Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 12
Submit an article Journal homepage
1,100
Views
8
CrossRef citations to date
0
Altmetric
Original Research

A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial

Jason F LesterVelindre NHS Trust, Velindre Cancer Centre, Cardiff, UKView further author information
,
Angela C CasbardWales Cancer Trials Unit, Centre for Trials Research, Cardiff University, Cardiff, UKView further author information
,
Saly Al-TaeiDivision of Cancer and Genetics, Cardiff University, Cardiff, UKView further author information
,
Richard HarropOxford BioMedica, Oxford, UKView further author information
,
Lajos KatonaWales Cancer Trials Unit, Centre for Trials Research, Cardiff University, Cardiff, UKView further author information
,
Richard L AttanoosDepartment of Cellular Pathology, Cardiff and Vale University Health Board and Cardiff University, Cardiff, UKView further author information
,
Zsuzsanna TabiDivision of Cancer and Genetics, Cardiff University, Cardiff, UKCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8427-1809View further author information
ORCID Icon &
Gareth O GriffithsWales Cancer Trials Unit, Centre for Trials Research, Cardiff University, Cardiff, UK;Clinical Trials Unit, Faculty of Medicine, University of Southampton, Southampton, UKView further author information
 show all
Article: e1457597 | Received 28 Nov 2017, Accepted 20 Mar 2018, Published online: 07 Sep 2018

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now

Articles from other publishers (7)

Shuhang Wang, Yuqi Yang, Lu Li, Peiwen Ma, Yale Jiang, Minghui Ge, Yue Yu, Huiyao Huang, Yuan Fang, Ning Jiang, Huilei Miao, Hao Guo, Linlin Yan, Yong Ren, Lichao Sun, Yan Zha & Ning Li. (2022) Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development. Vaccines 10:8, pages 1168.
Crossref
Ying He, Jing Wang, Shuangshuang Xie & Qianlong Xue. (2022) Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer. Frontiers in Surgery 9.
Crossref
Danijela Štrbac & Vita Dolžan. (2022) Novel and Future Treatment Options in Mesothelioma: A Systematic Review. International Journal of Molecular Sciences 23:4, pages 1975.
Crossref
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón-Terán & Angélica Meneses-Acosta. (2021) Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Frontiers in Pharmacology 12.
Crossref
Roger A. Smith, David J. Zammit, Nitin K. Damle, Helen Usansky, Sanjeeva P. Reddy, Jun-Hsiang Lin, Mahesh Mistry, Niranjan S. Rao, Louis J. Denis & Sandeep Gupta. (2021) ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Molecular Cancer Therapeutics 20:8, pages 1327-1337.
Crossref
Benjamin Wolfson & James W. Hodge. (2021) Next Generation Therapeutic Strateg‐Es: Evolving cancer immunotherapy through agents that Engage , Expand and Enable the anti‐tumor immune response . ImmunoMedicine 1:1.
Crossref
Mariana V. Ferreira, Elisa T. Cabral & Ana Sofia Coroadinha. (2020) Progress and Perspectives in the Development of Lentiviral Vector Producer Cells. Biotechnology Journal 16:1, pages 2000017.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.